+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031

  • ID: 5450266
  • Report
  • August 2021
  • Region: Global
  • 234 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioRestorative Therapies
  • DanDrit Biotech
  • Iovance Biotherapeutics
  • Northwest Biotherapeutics
  • Sclnow Biotechnology

Overview

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains. 

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable/raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and/or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Scope of the Report

The “Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031” report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. 

Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
  • An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area), service strength (based on its experience and company size) and number of products offered.
  • A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
  • Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
  • An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
  • An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
  • An elaborate discussion on the future opportunities/trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players, across the world, engaged in offering consumables for cell therapies?
  • Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
  • Which are the most popular media components used for cell therapy consumables?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
  • What are the key challenges associated with cell therapy consumables?
  • What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to consumables market for cell therapies?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioRestorative Therapies
  • DanDrit Biotech
  • Iovance Biotherapeutics
  • Northwest Biotherapeutics
  • Sclnow Biotechnology

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Context and Background
3.2. Chapter Overview
3.3. Introduction to Cell Therapies
3.3.1. Comparison of Cell Therapies and Other Biotechnology Products
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development
3.7. Type of Cell Therapy Consumable
3.8. Key Challenges Associated with Cell Therapy Consumables
3.9. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Therapy Kit Providers: List of Players
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Kits Preparation Facilities
4.2.5. Analysis by Accreditations Received
4.2.6. Analysis by Type of End-User
4.2.7. Analysis by Type of Cell Therapy
4.2.8. Analysis by Type of Function
4.2.9. Analysis by Scale of Operation
4.2.10. Analysis by Application Area
4.2.11. Analysis by Application Area and Geography (Regional Landscape)
4.3. Cell Therapy Media Providers: List of Players
4.3.1. Analysis by Year of Establishment 
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Location of Media Preparation Facilities
4.3.5. Analysis by Accreditations Received
4.3.6. Analysis by Type of End-User
4.3.7. Analysis by Type of Cell Therapy
4.3.8. Analysis by Media Components
4.3.9. Analysis by Type of Function
4.3.10. Analysis by Scale of Operation
4.3.11. Analysis by Application Area
4.3.12. Analysis by Application Area and Geography (Regional Landscape)
4.4. Cell Therapy Reagent Providers: List of Players
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Location of Reagent Preparation Facilities
4.4.5. Analysis by Accreditations Received
4.4.6. Analysis by Type of End-User
4.4.7. Analysis by Type of Cell Therapy
4.4.8. Analysis by Type of Function
4.4.9. Analysis by Scale of Operation
4.4.10. Analysis by Application Area
4.4.11. Analysis by Application Area and Geography (Regional Landscape)
4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Company Competitiveness: Kit Providers
5.5. Company Competitiveness: Media Providers
5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview 
6.2. Scope and Methodology
6.3. Bio-Techne
6.4. Miltenyi Biotec
6.5. Sartorius
6.6. STEMCELL Technologies
6.7. Thermo Fisher Scientific

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Miltenyi Biotec
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. STEMCELL Technologies
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Bio-Techne
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Irvine Scientific
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. Thermo Fisher Scientific
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Sartorius
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. BD Biosciences
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. Lonza
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.3. Recent Developments and Future Outlook
7.10. CellGenix
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.3. Recent Developments and Future Outlook
7.11. Corning
7.11.1. Company Overview
7.11.2. Product Portfolio
7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES 
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Consumable
8.3.5. Analysis by Type of Partnership and Type of Consumable
8.3.6. Analysis by Type of Cell Therapy
8.3.7. Analysis by Type of Consumable and Type of Cell Therapy
8.3.8. Most Active Players: Analysis by Number of Partnerships 
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Agreements
8.3.9.2. Local and International Agreements
8.3.10. Cumulative Year-wise Trend of Merger / Acquisition
8.3.11. Analysis by Type of Acquisition
8.3.12. Analysis by Key Value Drivers
8.3.13. Analysis by Year of Acquisition and Key Value Drivers
8.4. Cell Therapy Consumables: Recent Expansions
8.4.1. Analysis by Year of Expansion
8.4.2. Analysis by Purpose of Expansion
8.4.3. Analysis by Year and Purpose of Expansion
8.4.4. Analysis by Type of Consumable
8.4.5. Analysis by Purpose of Expansion and Type of Consumable
8.4.6. Analysis by Area of Expansion
8.4.7. Analysis by Region 
8.4.7.1. Analysis by Location of Consumable Facility (Continent-wise)
8.4.7.2. Analysis by Location of Consumable Facility (Country-wise)
8.4.8. Analysis by Purpose of Expansion and Location of Headquarters

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS   
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions 
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers
9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers 
9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers 
9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers 

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Demand for Cell Therapy Consumables
10.4. Global Demand for Cell Therapy Consumables for Planar Processes
10.5. Global Demand for Cell Therapy Consumables for Suspension Processes
10.6. Analysis by Scale of Operation
10.7. Analysis by Region 

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Global Outsourced Cell Therapy Consumables Market, 2021-2031
11.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable
11.4.1. Outsourced Cell Therapy Consumables Market for Kits, 2021-2031
11.4.2. Outsourced Cell Therapy Consumables Market for Media, 2021-2031
11.4.3. Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031
11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy
11.5.1. Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031
11.5.2. Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031
11.5.3. Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031
11.5.4. Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031
11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation
11.6.1. Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031
11.6.2. Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031
11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User
11.7.1. Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031
11.7.2. Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031
11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography
11.8.1. Outsourced Cell Therapy Consumables Market in North America, 2021-2031
11.8.2. Outsourced Cell Therapy Consumables Market in Europe, 2021-2031
11.8.3. Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031
11.8.4. Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
12.1. Chapter Overview
12.2. Emerging Trends Related to Cell Culture Media
12.3. Automation of Cell Therapy Manufacturing Processes 
12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market
13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers
13.4. Current Opinions and Key Initiatives of Key Players
13.5. Recuperative Strategies for Developer Businesses
13.5.1. Strategies for Implementation in the Short / Mid Term
13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS
14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS
15.1. Chapter Overview
15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies
15.2.1. Cellular Engineering Technologies: Key Highlights
15.2.2. Interview Transcript
15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories
15.3.1. HiMedia Laboratories: Key Highlights
15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • 3P Biopharmaceuticals
  • Accellta
  • Acer Therapeutics
  • Activartis Biotech
  • Adaptimmune
  • Adicet Bio
  • Aduro Biotech
  • Advent Bioservices
  • AGC Biologics
  • AgenTus Therapeutics
  • Agilent Technologies
  • Ajinomoto
  • Akadeum Life Sciences
  • Akron Biotech
  • Allele Biotechnology and Pharmaceuticals
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Altor BioScience
  • American CryoStem
  • Amphera
  • AMSBIO
  • Anhui Kedgene Biotechnology
  • ANI Pharmaceuticals
  • apceth Biopharma
  • Applied Biological Materials
  • Arbele
  • Arcline Investment Management
  • Argos Therapeutics
  • Aspire Health Science
  • Astellas Pharma
  • Asterias Biotherapeutics
  • AstraZeneca
  • Atara Biotherapeutics
  • ATCC
  • Athersys
  • Atlantis Bioscience
  • Atreca Therapeutics
  • Aurora Biopharma
  • Austrianova
  • Autolus
  • Avantor
  • AVAX Technologies
  • Axol Bioscience
  • Basic Pharma
  • Baxalta
  • Baxter
  • BD Biosciences
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Immunochina Medical Science & Technology
  • Beijing Sanwater Biological Technology
  • Beijing Tricision Biotherapeutics 
  • Beike Biotechnology
  • Bellicum Pharmaceuticals
  • Bio Elpida
  • BioAtla
  • BioCardia
  • BioCare
  • BioCentriq
  • Bio-Connect
  • Bioinova
  • Biological Industries
  • BioNTech
  • BioRestorative Therapies
  • Bio-Techne 
  • bluebird bio
  • Bone Therapeutics
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • C3i (Center of Excellence for Cellular Therapy)
  • Caladrius Biosciences
  • Capricor Therapeutics
  • Captain T Cell
  • CardioCell
  • Carina Biotech
  • CARsgen Therapeutics
  • CAR-T (Shanghai) Biotechnology
  • Cartherics
  • Catalent Biologics
  • Celgene
  • Celixir
  • Cell and Gene Therapy Catapult
  • Cell Applications
  • Cell Biologics
  • Cell Biotech
  • Cell Genesys
  • Cell Therapies
  • Cellaria
  • Cell-Easy
  • Cellectis
  • Cellex Cell Professionals
  • CellGenix
  • Cellin Technologies
  • Cellmed
  • CellMP (A subsidiary of Emmecell)
  • CELLnTEC Advanced Cell Systems
  • CellPraxis
  • CellProtect Nordic Pharmaceuticals
  • CellProthera
  • Cells Online
  • Cellular Biomedicine Group
  • Cellular Engineering Technologies
  • Cellular Therapeutics
  • Celonic
  • Celprogen
  • Celularity
  • Celyad
  • Censo Biotechnologies
  • CHA Biolab
  • Chengdu MedGenCell
  • China Regenerative Medicine International
  • CiMaas
  • Clean Cells
  • CO.DON
  • Cogent Biosciences
  • Cognate BioServices
  • CoImmune
  • Cook MyoSite
  • Corestem
  • Corning
  • Creative Biolabs
  • CRISPR Therapeutics
  • Cyagen Biosciences
  • Cytiva (A subsidiary of Danaher)
  • Cytopeutics
  • CytoSen Therapeutics (Acquired by Kiadis Pharma)
  • Cytovac
  • CyTuVax 
  • Daiichi Sankyo
  • DanDrit Biotech
  • DCPrime
  • Delta-Vir
  • Dendreon
  • DiscGenics
  • ElevateBio
  • Eli Lilly
  • Endocyte
  • Eureka Therapeutics
  • Eutilex
  • Ever Union Biotechnology 
  • EXUMA Biotech
  • Fate Therapeutics
  • Ferrer Internacional
  • Fibrocell Technologies
  • Five Prime Therapeutics
  • Formula Pharmaceuticals
  • Fortress Biotech
  • Fosun Kite Biotechnology
  • Froceth
  • Fujilfim Cellular Dynamics
  • Fujifilm
  • Gadeta
  • Gamida Cell
  • GC Cell (Formerly known as Green Cross Cell)
  • Gemini Bio
  • GenCure (A subsidiary of BioBridge Global)
  • Genentech
  • GenIbet Biopharmaceuticals
  • Genzyme
  • GigaGen 
  • GlaxoSmithKline
  • Global Cell Med
  • Glycostem Therapeutics
  • Gradalis
  • Green Cross
  • GRI Bio
  • Guangzhou Trinomab Biotech
  • Heat Biologics
  • Hebei Senlang Biotechnology
  • Hemostemix
  • HengRui YuanZheng Bio-Technology
  • HiMedia Laboratories
  • Histocell
  • Histogenics
  • Holostem Terapie Avanzate
  • Hunan Zhaotai Yongren Biotech
  • IBA Lifesciences
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Immatics
  • Immune Therapeutics
  • Immunicum
  • ImmunoCellular Therapeutics
  • Immunocore
  • Immunovative Therapies 
  • Immutep
  • IncoCell Tianjin (wholly-owned subsidiary of Boyalife Group)
  • Incysus
  • Innoprot
  • Innovative Cellular Therapeutics
  • Inovio Pharmaceuticals
  • inRegen
  • Intellia Therapeutics
  • International Stem Cell Corporation
  • InVitria
  • Iovance Biotherapeutics
  • Irvine Scientific (Acquired by FUJIFILM)
  • ISTO Technologies
  • Ivy Life Sciences
  • iXCells Biotechnologies
  • Janssen
  • Japan Tissue Engineering
  • Juno Therapeutics
  • JW Biotechnology
  • JW CreaGene
  • Kadimastem
  • Kangstem Biotech
  • KBI Biopharma
  • Kiadis Pharma
  • Kiromic
  • Kite Pharma
  • Kuur Therapeutics
  • LAgen Laboratories
  • Laurus Bio (Formerly known as Richcore Lifesciences)
  • Laurus Labs
  • Legend Biotech
  • Leucid Bio
  • Lifecells
  • Lineage Cell Therapeutics
  • Lion TCR
  • Living Pharma
  • Longeveron
  • Lonza
  • Lumos Pharma
  • Lykan Bioscience
  • Marino Biotechnology
  • MaxCyte
  • Medeor Therapeutics
  • Medigene
  • MEDINET
  • MEDIPOST
  • MedVax Technologies
  • Merck Serono
  • Mesoblast
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • Minerva Biotechnologies
  • Minovia Therapeutics
  • MolecuVax
  • Moraga Biotechnology
  • Multimmune
  • Mustang Bio 
  • Nanjing KAEDI Biotech
  • NantKwest
  • Neopharm
  • Neuralstem
  • Neuromics
  • Nikon CeLL innovation
  • Nkarta
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Northern Therapeutics
  • Northwest Biotherapeutics
  • Novadip Biosciences
  • Novartis
  • NovaRx (Acquired by Viropro)
  • Novella Clinical
  • Novex Innovations
  • Nucleus Biologics
  • Nuo Therapeutics
  • OhioHealth
  • OiDE BetaRevive
  • Ology Bioservices
  • Oncobiomed
  • Opexa Therapeutics
  • Orchard Therapeutics
  • OrganaBio
  • Osiris Therapeutics
  • Oxford BioMedica
  • PAN-Biotech
  • PDC*line Pharma
  • PELOBiotech
  • PeproTech
  • PersonGen BioTherapeutics
  • Pfizer
  • PharmaBio
  • Pharmicell
  • PhoenixSongs Biologicals
  • Pinze Lifetechnology
  • Pique Therapeutics
  • Pluristem Therapeutics
  • Plus Therapeutics
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Preferred Cell Systems™
  • Pregene ShenZhen Biotechnology
  • Primorigen Biosciences (Acquired by Nucleus Biologics)
  • ProMab Biotechnologies
  • Promethera Biosciences
  • PromoCell
  • Provia Laboratories
  • R&D Systems (Formerly known as Atlanta Biologicals)
  • ReachBio Research Labs
  • Regeneris Medical
  • Regeneron
  • Regeneus
  • ReNeuron
  • REPROCELL
  • Rexgenero
  • RHEACELL
  • Riyadh Pharma
  • RoosterBio
  • Roslin Cell Therapies
  • Rubius Therapeutics
  • S.Biomedics
  • Sangamo Therapeutics
  • Sanvitra
  • Saronic Biotechnology
  • Sartorius
  • ScienCell Research Laboratories
  • Sclnow Biotechnology
  • SCM Lifescience
  • Seattle Genetics
  • Sentien Biotechnologies
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai GeneChem
  • Shanghai Houchao Biotechnology
  • Shanghai iCELL Biotechnology
  • Shanghai Longyao Biotechnology
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shenzhen BinDeBio
  • Shenzhen Hornetcorn Biotechnology
  • Shionogi
  • Sigma-Aldrich (Acquired by Merck)
  • Sinobioway Cell Therapy
  • SMT Bio
  • Sorrento Therapeutics
  • SOTIO
  • SQZ Biotech
  • Stem Cell Arabia
  • STEMCELL Technologies
  • StemImmune
  • Stemmatters 
  • Sumitomo Dainippon Pharma
  • Super-T Cell Cancer Company
  • Surface Oncology
  • Tactiva Therapeutics
  • Taiwan Bio Therapeutics
  • Takara Bio
  • Takeda Pharmaceutical
  • TapImmune 
  • Targazyme
  • TC BioPharm
  • TCR2 Therapeutics
  • Tella
  • Tessa Therapeutics
  • The Discovery Labs Center for Breakthrough Medicines
  • Thermo Fisher Scientific
  • ThermoGenesis
  • Tianhe Stem Cell Biotechnologies
  • TiGenix
  • TILT Biotherapeutics
  • Tmunity Therapeutics
  • TNK Therapeutics
  • TotipotentRX
  • TRACT Therapeutics
  • TransCure BioServices
  • TreeFrog Therapeutics
  • Trinova Biochem
  • Triumvira Immunologics
  • TVAX Biomedical
  • Universal Cells
  • U.S. Stem Cell
  • Vaccinogen
  • Vericel
  • VetStem Biopharma
  • ViroMed
  • Viscofan BioEngineering
  • Vitro Biopharma
  • Waisman Biomanufacturing
  • West Biotherapy
  • Wissenschaftlicher Service Pharma (WiSP)
  • Wuhan Sian Medical Technology
  • WuXi AppTec (WuXi Advanced Therapies)
  • Xcell Therapeutics
  • Xcelthera
  • XEME Biopharma
  • Zelluna Immunotherapy 
  • Zimmer Biomet
  • Ziopharm Oncology
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll